Incidence and Management of Retinopathy and Uveitis in Patients Receiving BRAF/MEK Inhibitor Therapy.

IF 2.3 4区医学 Q2 OPHTHALMOLOGY Seminars in Ophthalmology Pub Date : 2025-11-01 Epub Date: 2025-02-24 DOI:10.1080/08820538.2025.2468381

Isana Nakajima, Koji Yoshino, Hideki Tsuji

{"title":"Incidence and Management of Retinopathy and Uveitis in Patients Receiving BRAF/MEK Inhibitor Therapy.","authors":"Isana Nakajima, Koji Yoshino, Hideki Tsuji","doi":"10.1080/08820538.2025.2468381","DOIUrl":null,"url":null,"abstract":"Purpose: To assess the clinical features of ocular adverse events in patients receiving BRAF/MEK inhibitor therapy.Methods: In this retrospective study, 65 patients were treated with BRAF/MEK inhibitors (dabrafenib/trametinib or encorafenib/binimetinib).Results: Of the 65 patients, 28 had malignant melanoma and 37 had non-melanoma malignancies. Bilateral MEK-associated retinopathy was observed in nine cases; none experienced vision loss due to MEK-associated retinopathy. Uveitis was diagnosed in four patients (6.1%), three of whom presented with Vogt-Koyanagi-Harada (VKH)-like uveitis. All VKH-like uveitis cases were observed in patients with melanoma and their incidences were significantly higher in these patients than in those without melanoma (p = .04). Treatment with corticosteroids resulted in either resolution or control of symptoms in all cases of VKH-like uveitis, enabling continuation of BRAF/MEK inhibitor therapy.Conclusion: VKH-like uveitis was found to be significantly more frequent in patients with melanoma than in those with other malignancies.","PeriodicalId":21702,"journal":{"name":"Seminars in Ophthalmology","volume":" ","pages":"775-781"},"PeriodicalIF":2.3000,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08820538.2025.2468381","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/24 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To assess the clinical features of ocular adverse events in patients receiving BRAF/MEK inhibitor therapy.

Methods: In this retrospective study, 65 patients were treated with BRAF/MEK inhibitors (dabrafenib/trametinib or encorafenib/binimetinib).

Results: Of the 65 patients, 28 had malignant melanoma and 37 had non-melanoma malignancies. Bilateral MEK-associated retinopathy was observed in nine cases; none experienced vision loss due to MEK-associated retinopathy. Uveitis was diagnosed in four patients (6.1%), three of whom presented with Vogt-Koyanagi-Harada (VKH)-like uveitis. All VKH-like uveitis cases were observed in patients with melanoma and their incidences were significantly higher in these patients than in those without melanoma (p = .04). Treatment with corticosteroids resulted in either resolution or control of symptoms in all cases of VKH-like uveitis, enabling continuation of BRAF/MEK inhibitor therapy.

Conclusion: VKH-like uveitis was found to be significantly more frequent in patients with melanoma than in those with other malignancies.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

接受BRAF/MEK抑制剂治疗的患者视网膜病变和葡萄膜炎的发病率和管理

目的：评价BRAF/MEK抑制剂治疗患者眼部不良事件的临床特点。方法：在这项回顾性研究中，65例患者接受BRAF/MEK抑制剂（dabrafenib/trametinib或encorafenib/binimetinib）治疗。结果：65例患者中，恶性黑色素瘤28例，非黑色素瘤37例。双侧mek相关视网膜病变9例；没有人因mek相关视网膜病变而出现视力丧失。4例（6.1%）患者被诊断为葡萄膜炎，其中3例表现为Vogt-Koyanagi-Harada （VKH）样葡萄膜炎。所有vkh样葡萄膜炎均发生在黑色素瘤患者中，其发病率明显高于无黑色素瘤患者（p = 0.04）。在所有vkh样葡萄膜炎病例中，皮质类固醇治疗均可缓解或控制症状，从而使BRAF/MEK抑制剂治疗得以继续。结论：vkh样葡萄膜炎在黑色素瘤患者中的发生率明显高于其他恶性肿瘤患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Seminars in Ophthalmology OPHTHALMOLOGY-

CiteScore

3.20

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Seminars in Ophthalmology offers current, clinically oriented reviews on the diagnosis and treatment of ophthalmic disorders. Each issue focuses on a single topic, with a primary emphasis on appropriate surgical techniques.